RECAPTURE 04: Phase 3 study of CAZ-AVI vs Doripenum in Complicated UTI

• Research type

  Research Study

• Full title

  A Phase III, Randomized, Multicenter, Double-Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime-Avibactam (CAZ-AVI, formerly CAZ104)Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, With a Gram-Negative Pathogen in Hospitalized Adults

• IRAS ID

  124250

• Contact name

  Matthew Dryden

• Contact email

  matthew.dryden@hhft.nhs.uk

• Sponsor organisation

  AstraZeneca AB

• Eudract number

  2011-005722-21

• Clinicaltrials.gov Identifier

  n/a

• REC name

  South Central - Hampshire A Research Ethics Committee

• REC reference

  13/SC/0367

• Date of REC Opinion

  25 Oct 2013

• REC opinion

  Further Information Favourable Opinion